Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses.

Campbell, Katrin; Young, Vivienne L; Donaldson, Braeden C; Woodall, Matthew J; Shields, Nicholas J; Walker, Greg F; Ward, Vernon K; Young, Sarah L

Campbell, Katrin; Young, Vivienne L; Donaldson, Braeden C; Woodall, Matthew J; Shields, Nicholas J; Walker, Greg F; Ward, Vernon K; Young, Sarah L.

Afiliación

Campbell K; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9016, New Zealand.
Young VL; Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
Donaldson BC; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9016, New Zealand.
Woodall MJ; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9016, New Zealand.
Shields NJ; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney 2006, Australia.
Walker GF; School of Pharmacy, University of Otago, Dunedin 9016, New Zealand.
Ward VK; Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand.
Young SL; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney 2006, Australia.

Vaccines (Basel) ; 9(5)2021 May 06.

Article en En | MEDLINE | ID: mdl-34066318

Palabras clave

breast cancer; cancer immunotherapy; conjugated VLPs; multimeric presentation; nanoparticles; therapeutic vaccines; virus-like particles (VLPs)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Nueva Zelanda